Skip to main content
OpenTrials
Completed

NCT Number: NCT04578678

Can Subthalamic Stimulation Using Directional Electrodes Improve Postoperative Management in Parkinson's Disease

The primary objective of the study is to determine if subthalamic nucleus (STN) deep brain stimulation (DBS) using the Vercise directional leads improves neuropsychiatric state and neuropsychiatric fluctuations 12 months after surgery in a large consecutive series of STN-DBS Parkinson's disease (PD) patients.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This project of further use of health-related data with consent by the participants is a prospective, international project to evaluate the improvement of neuropsychiatric symptoms and the quality of life 12 months after surgery in a large consecutive series of STN-DBS PD patients using novel implantable Neurostimulator Systems (Boston Scientific). The project will investigate if a fine tuning of the STN-DBS settings could alleviate neuropsychiatric fluctuations, apathy as well as DBS-induced dysarthria and global motor state. The tuning is performed in agreement with the instruction for use of all devices used. Further objectives are validation of new tools that are presently entering clinical routine in optimizing postoperative management like individual current sources, steering, imaging of volume of tissue activated, and beta-oscillations.

The data originates from patients suffering from levodopa-responsive PD which are not adequately controlled by dopaminergic medication and therefore receive STN-DBS as a routine standard of care with routinely collected data.

In total 110 patients who are candidates for STN-DBS will be enrolled in four participating sites in Switzerland and the EU.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

For all subjects:

  • Informed consent as documented by signature
  • Diagnosis of PD based on the MDS clinical diagnostic criteria for Parkinson's disease
  • Fulfilling criteria for STN-DBS:
  • The presence of disabling motor complications of dopaminergic treatment
  • The absence of surgical contraindications
  • Planned bilateral STN-DBS using steering electrodes in the next 3 months (routine standard of care)

Exclusion criteria

  • Presence of dementia as indicated by a score ≤ 25 on the MOntreal Cognitive Assessment (MOCA)
  • Depression with acute suicidal ideation
  • Presence of major ongoing psychiatric illness
  • Non-compensated systemic disease (i.e., diabetes, hypertension)
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant
  • Participation in interventional trial within the 30 days preceding and during the present study
  • Previous enrolment into the current study
  • Enrolment of any study site personnel, their family members, employees or other dependent persons

Treatment and study plan

Steering

Other

Fine tuning of the STN-DBS settings

Primary outcomes

  1. Evaluation of non-motor fluctuations

    Time frame: Follow-up ≤ 5 Weeks

    Evaluation of the Neuropsychiatric Fluctuations Scale (NFS) in different states (ON/OFF) to evaluate if non-motor fluctuations are present. The bigger the difference between the two subscores ('ON psychological state' and 'OFF psychological sate') in the different states are, the more non-motor fluctuations are present.

Secondary outcomes

  1. Evaluation of motor improvement

    Time frame: Follow-up ≤ 5 Weeks

    Motor improvement following STN-DBS using the Vercise directional leads will be assessed by comparing MDS-UPDRS III score (International Parkinson and Movement Disorder Society) during the study in different states (ON/OFF). The minimum and maximum values are: 0-132, where a higher score means a worse outcome.

  2. Evaluation of STN-DBS induced dysarthria

    Time frame: Follow-up ≤ 5 Weeks

    Dysarthria will be measured during the study by Voice Handicap Index 30 (VHI) scale. The minimum and maximum values are: 0-120, where a higher score means a worse outcome.

  3. Evaluation of postoperative apathy

    Time frame: Follow-up ≤ 5 Weeks

    Apathy will be measured during the study by Dimensional Apathy Scale (DAS). The minimum and maximum values are: 0-72, where a higher score means a worse outcome.

Sponsors and collaborators

Lead sponsor

Insel Gruppe AG, University Hospital Bern

Other

Collaborators

  • Boston Scientific Corporation

Registry information

Official study title

Can Subthalamic Stimulation Using Directional Electrodes Improve Postoperative Management in Parkinson's Disease: A Post-market Study - Steeropt

Acronym: Steeropt

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Oct 8, 2020
Registry last updated
May 26, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.